<DOC>
	<DOCNO>NCT01012622</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Osmotic Release Oral System ( OROS ) methylphenidate participant Attention Deficit Hyperactivity Disorder ( ADHD ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Osmotic Release Oral System ( OROS ) Methylphenidate Participants With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>This open-label ( people involve know identity intervention ) , single arm , multicenter ( one hospital medical school team work medical research study ) , prospective study ( study follow participant forward time ) evaluate efficacy safety OROS methylphenidate participant ADHD ( behavior disorder originate childhood essential feature sign developmentally inappropriate inattention , impulsivity , hyperactivity ) . The study duration 12 week per participant , divide 2 part Screening ( within 14 day study commences Day -1 ) treatment ( 8 week include titration period [ initiation study treatment determination individual 's maintenance dose ] maintenance period [ least 4 week determination maintenance dose ] ) . Participants receive initial dose depend body weight . OROS methylphenidate hydrochloride ( HCL ) give orally daily initial dose 18 milligram ( mg ) participants 30 kilogram ( kg ) 27 mg 30 kg body weight . The dose increase 9 mg 18 mg every week Week 8 , follow maximum maintenance dose 54 mg orally daily Week 12 dose decrease 9 mg depend tolerability . Efficacy evaluated Korean Version , ADHD Rating Scale ( K-ARS ) total score Clinical Global Impression ) -Severity / Impression rating scale CGI-S/I . Participants safety monitor throughout trial .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Participants voluntarily provide informed consent participate study Participants write informed consent participate study voluntarily caregivers/legal representative Participants capable follow study visit schedule well parents/caregivers willing complete assessment specify protocol capable complete Participant his/her parent/guardian able understand study participation request withdrawal study voluntarily time Participants satisfied diagnosis Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) Attention Deficit Hyperactivity Disorder ( ADHD ) determine require drug therapy Participants know hypersensitivity ( altered reactivity antigen , result pathologic reaction upon subsequent exposure particular antigen ) methylphenidate HCL Participants significant suicidal ideation Participants mental retardation Participants meet DSMIV diagnostic criterion current major depressive disorder anxiety disorder require drug therapy Participants abnormalities Electrocardiography ( ECG ) show clinically significant abnormality laboratory result , include serum chemistry hematology</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>Methylphenidate Hydrochloride</keyword>
</DOC>